Why Sarepta Therapeutics Inc. (SRPT) Crashed On Tuesday?
We recently published a list of 10 Firms Heavily Hit by Market Pessimism. In this article, we are going to take a look at ...
STAT21m
Cargo Therapeutics ends development efforts
Cargo was founded by two highly acclaimed cell-therapy researchers. The company raised over $500 million to develop ...
Becker's Hospital Review15m
1st patient death in muscular dystrophy treatment
Cambridge, Mass.-based Sarepta Therapeutics reported the first known death from its Duchenne muscular dystrophy gene therapy ...
Teenager who received Elevidys, Sarepta’s Duchenne gene therapy, dies
Elevidys was approved after intense debate at the FDA, as officials and reviewers disagreed over how strong the evidence was ...
Ticker: Sarepta reports death in drug trial; Google makes $32B cybersecurity deal
Cambridge-based Sarepta Therapeutics said Tuesday that a patient died while taking its closely watched gene therapy for ...
Sarepta says teen died after its gene therapy treatment
Sarepta Therapeutics said on Tuesday that a 16-year-old boy died from acute liver failure months after receiving the company's U.S-approved gene therapy for a rare muscular dystrophy. The patient ...
StockStory.org on MSN22h
Why Sarepta Therapeutics (SRPT) Shares Are Sliding Today
Shares of biotech company Sarepta Therapeutics (NASDAQ:SRPT) fell 24.9% in the pre-market session after the company reported ...
Sarepta Therapeutics (NASDAQ:SRPT) Earns Overweight Rating from Cantor Fitzgerald
Cantor Fitzgerald reiterated their overweight rating on shares of Sarepta Therapeutics (NASDAQ:SRPT – Free Report) in a ...
Sarepta stock reaction overdone, says Barclays
Barclays reiterated an Overweight rating and $209 price target on Sarepta (SRPT) after the company reported a patient death post treatment of ...